Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is in the spotlight today after unveiling topline results from its pivotal Phase 3 RISE UP trial of mitapivat (Pyrukynd) in sickle cell disease (SCD) — data that are being widely described as “mixed” and have sent the stock sharply lower. GlobeNewswire+2Reuters+2 The study hit one of its two primary endpoints and showed strong effects on markers of hemolysis, but it failed to significantly reduce painful sickle cell crises or fatigue across the full study population — the outcomes many investors were most focused on. GlobeNewswire+2Reuters+2 Key Takeaways From Today’s Agios (AGIO) News What Agios